Elected SEHH President Claims Precision Lymphoma Treatments
- MADRID (Europa Press) — Precision medicine, targeted therapies, and collaborative research are transforming the fight against lymphomas in Spain, according to Armando López Guillermo, the elected president of...
- Guillermo's remarks came during the XXVI annual Gelthian Meeting, which convened approximately 170 hematologists and other specialists to discuss the latest breakthroughs in the diagnosis and treatment of...
- A key focus of the meeting was an update on the Spanish Lymphomas Registry (Reinf), a database containing clinical facts from over 29,000 patients across 40 hospitals.
Spanish Hematologists Highlight Advances in Lymphoma Treatment
Table of Contents
- Spanish Hematologists Highlight Advances in Lymphoma Treatment
- National registry Aids Research
- Clinical trials Explore new Therapies
- BTK Inhibitors Show Promise in mantle Cell Lymphoma
- Single-Cell Studies Offer new Insights
- Marginal Zone Lymphoma Treatment Advances
- Hodgkin Lymphoma: Tailoring Treatment for Older Patients
- consolidation Therapy for Hodgkin Lymphoma
- Breakthroughs in Lymphoma Treatment: A Q&A wiht Spanish Hematologists
- What are the latest advancements in lymphoma treatment?
- What is lymphoma?
- Where are these advancements taking place?
- What is the Spanish Lymphomas Registry (Reinf)?
- What clinical trials are underway in Spain to improve lymphoma treatment?
- What are BTK inhibitors, and how are they impacting mantle cell lymphoma (MCL) treatment?
- what are single-cell studies, and how are they improving lymphoma research?
- How is marginal zone lymphoma being treated?
- How is Hodgkin lymphoma treatment being tailored for older patients?
- What is consolidation therapy for Hodgkin lymphoma?
- Summary of Key Advancements
MADRID (Europa Press) — Precision medicine, targeted therapies, and collaborative research are transforming the fight against lymphomas in Spain, according to Armando López Guillermo, the elected president of the Spanish Society of Hematology and Hemotherapy (SEHH) and president of the Spanish group of lymphomas and autologous bone marrow transplantation (Geltram).
Guillermo’s remarks came during the XXVI annual Gelthian Meeting, which convened approximately 170 hematologists and other specialists to discuss the latest breakthroughs in the diagnosis and treatment of lymphomas. Lymphomas are a diverse group of cancers, encompassing around 60 different types, that affect the lymphatic system, a crucial component of the immune system.
National registry Aids Research
A key focus of the meeting was an update on the Spanish Lymphomas Registry (Reinf), a database containing clinical facts from over 29,000 patients across 40 hospitals. This national resource allows researchers to gain a deeper understanding of lymphoma trends in Spain and tailor treatment strategies accordingly.
Clinical trials Explore new Therapies
Geltram is currently coordinating 13 clinical trials aimed at improving treatment outcomes for common lymphoma subtypes. these trials include five focusing on diffuse large B-cell lymphoma (DLBCL), five on mantle cell lymphoma (MCL), two on Hodgkin lymphoma, and one on follicular lymphoma.
BTK Inhibitors Show Promise in mantle Cell Lymphoma
Eva Giné, from the Clinic Hospital in Barcelona, highlighted progress in treating MCL with BTK inhibitors. These drugs target a protein essential for the survival of tumor cells and are moving toward becoming a first-line treatment option. “These treatments are already beginning to be used in combination with immunoquimotherapy on the front line, and are displacing bone marrow transplantation in some cases,” Giné said.
Single-Cell Studies Offer new Insights
Miguel Alcoceba, a specialist at Salamanca University Hospital and coordinator of the Pathology and Molecular Biology Working Group, presented the latest advancements in single-cell studies. This technology allows researchers to analyze individual tumor cells, revealing subtle differences and information that may be missed by conventional techniques.
Marginal Zone Lymphoma Treatment Advances
Updated data from the clinical trial ‘IELSG48’ were presented, comparing the combination of Zanubrutinib and Rituximab with Rituximab alone in the treatment of marginal zone lymphoma. Additionally, results from a real-world study involving 101 patients with relapsed or refractory marginal zone lymphoma treated with Zanubrutinib were shared.
Hodgkin Lymphoma: Tailoring Treatment for Older Patients
eva Domingo, a specialist at the hospitale-Hospital Durán I Reynals in Barcelona and coordinator of the Hodgkin Lymphoma working Group, noted the emergence of new targeted therapies for older patients with advanced Hodgkin lymphoma. The combination of these therapies in relapse cases may, in some instances, eliminate the need for bone marrow transplantation. Researchers are also exploring the possibility of omitting radiotherapy in early stages of the disease without compromising treatment effectiveness.
consolidation Therapy for Hodgkin Lymphoma
Pilar Sarandeses, of the 12 de Octubre University Hospital in Madrid and coordinator of the Geltamo Diagnostic Working Group, detailed the phase II ‘brecellibet/Geltamo18-HL’ trial. This trial is evaluating the use of Brentuximab Vedotin as a consolidation treatment in patients with classic Hodgkin lymphoma in relapse or refractory bone marrow who achieve a complete response after rescue therapy.
Breakthroughs in Lymphoma Treatment: A Q&A wiht Spanish Hematologists
What are the latest advancements in lymphoma treatment?
According to experts, including those at the XXVI annual Gelthian Meeting, precision medicine, targeted therapies, and collaborative research are revolutionizing the fight against lymphomas.
What is lymphoma?
Lymphoma is a diverse group of cancers that affect the lymphatic system, a crucial part of the immune system. There are approximately 60 different types of lymphoma.
Where are these advancements taking place?
These advancements are being highlighted by Spanish hematologists, as discussed at the Gelthian Meeting.
What is the Spanish Lymphomas Registry (Reinf)?
The Spanish Lymphomas Registry (Reinf) is a crucial national resource. It is a database containing clinical data from over 29,000 patients across 40 hospitals. This registry helps researchers understand lymphoma trends in Spain and tailor treatment strategies.
What clinical trials are underway in Spain to improve lymphoma treatment?
Geltram is currently coordinating 13 clinical trials to improve treatment outcomes for common lymphoma subtypes. These trials focus on:
Diffuse large B-cell lymphoma (DLBCL) (5 trials)
Mantle cell lymphoma (MCL) (5 trials)
Hodgkin lymphoma (2 trials)
Follicular lymphoma (1 trial)
What are BTK inhibitors, and how are they impacting mantle cell lymphoma (MCL) treatment?
BTK (Bruton’s tyrosine kinase) inhibitors are showing promise in treating mantle cell lymphoma (MCL). These drugs target a protein vital for tumor cell survival. Experts like Eva Giné from the Clinic Hospital in Barcelona have highlighted advancements, indicating that these treatments are moving toward becoming first-line treatment options. They are being used in combination with immunoquimotherapy and are, in certain specific cases, replacing bone marrow transplantation.
what are single-cell studies, and how are they improving lymphoma research?
Single-cell studies involve analyzing individual tumor cells to reveal subtle differences that might be missed by customary techniques. Miguel Alcoceba from Salamanca University Hospital presented the latest advancements in this technology.
How is marginal zone lymphoma being treated?
Updated data from the clinical trial ‘IELSG48’ were presented, comparing the combination of Zanubrutinib and Rituximab with Rituximab alone. Additionally, results from a real-world study of 101 patients with relapsed or refractory marginal zone lymphoma treated with Zanubrutinib were shared.
How is Hodgkin lymphoma treatment being tailored for older patients?
New targeted therapies are emerging for older patients with advanced Hodgkin lymphoma. In some cases of relapse, these therapies might eliminate the need for bone marrow transplantation. Researchers are also exploring the possibility of omitting radiotherapy in early stages without compromising treatment effectiveness.
What is consolidation therapy for Hodgkin lymphoma?
Pilar Sarandeses of the 12 de Octubre University hospital in Madrid detailed the phase II ‘brecellibet/Geltamo18-HL’ trial. This trial is evaluating Brentuximab Vedotin as a consolidation treatment for patients with classic Hodgkin lymphoma in relapse or refractory bone marrow who achieve a complete response after rescue therapy.
Summary of Key Advancements
Here’s a summary of the key areas of advancement discussed at the Gelthian Meeting:
| Area of Advancement | Key Details |
| :————————– | :———————————————————————————————————————————————– |
| Precision Medicine | Tailoring treatment to the specific characteristics of the lymphoma. |
| Targeted Therapies | Drugs that specifically target cancer cells, such as BTK inhibitors. |
| Collaborative Research | Pooling data and resources nationally, e.g., Spanish Lymphomas Registry (reinf) |
| BTK Inhibitors (MCL) | Showing positive results in mantle cell lymphoma, potentially becoming a first-line treatment in combination with immunoquimotherapy. |
| Single-Cell Studies | Allow for a deeper understanding of individual tumor cells. |
| Marginal Zone Lymphoma | Evaluating new treatment combinations. |
| Hodgkin Lymphoma (Older Patients) | Progress of new, targeted therapies, and exploring ways to reduce or eliminate radiotherapy. |
| Consolidation Therapy | utilizing drugs like Brentuximab Vedotin to improve outcomes after initial treatment in Hodgkin lymphoma. |